Effects of strontium ranelate, raloxifene and misoprostol on bone mineral density in ovariectomized rats

Basit Öğe Kaydı
dc.authoridDURMUS ALTUN, GULAY/0000-0002-1822-9386
dc.authorwosidDURMUS ALTUN, GULAY/S-6586-2016
dc.contributor.authorAhmet-Camcioglu, Nefise
dc.contributor.authorOkman-Kilic, Tulay
dc.contributor.authorDurmus-Altun, Gulay
dc.contributor.authorEkuklu, Galip
dc.contributor.authorKucuk, Mustafa
dc.date.accessioned2024-06-12T11:11:47Z
dc.date.available2024-06-12T11:11:47Z
dc.date.issued2009
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjectives: To investigate the effects of strontium ranelate, raloxifene and misoprostol on bone mineral density (BMD) in ovariectomized rats to contribute to the individualization of the treatment of postmenopausal osteoporosis. Study design: Sixty sexually mature female Sprague-Dawley rats weighing 250 g were used. The 60 rats were divided into six groups of 10 rats each: SR, MISO, RAL, SHAM, DW and OVX All except the SHAM rats were subjected to bilateral ovariectomy. Three days after surgery, rats were administered strontium ranelate (Protelos (R), 2 g, Servier, Istanbul), 1800 mg/kg/day; misoprostol (Cytotec (R), 200 mcg, Ali Raif, Istanbul), 200 mcg/kg/day; raloxifene (Evista (R), 60 mg, Lily and Company, Istanbul), 3 mg/kg/day and 1 cc of distilled water by gavage for 8 weeks. Bone mineral density measurements were then performed. Results: The strontium ranelate (SR) group had significantly higher vertebral BMD than all other groups. Femoral density in the SR group was also significantly higher than in other groups and there was no difference between femoral density in the strontium ranelate and sham groups. Conclusions: Strontium ranelate, raloxifene and misoprostol can prevent bone loss in the vertebrae, whereas strontium ranelate can also prevent bone loss in the femur of ovariectomized rats. Strontium ranelate increases greater than raloxifene and misoprostol BMD in the vertebrae. Condensation: Strontium ranelate may increase both vertebral and femur BMD in ovariectomized rats while raloxifene and misoprostol may only increase lumbar spine BMD. Crown Copyright (C) 2009 Published by Elsevier Ireland Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.ejogrb.2009.09.001
dc.identifier.endpage194en_US
dc.identifier.issn0301-2115
dc.identifier.issn1872-7654
dc.identifier.issue2en_US
dc.identifier.pmid19796864en_US
dc.identifier.scopus2-s2.0-71849104186en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage192en_US
dc.identifier.urihttps://doi.org/10.1016/j.ejogrb.2009.09.001
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22930
dc.identifier.volume147en_US
dc.identifier.wosWOS:000272787900015en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Bven_US
dc.relation.ispartofEuropean Journal Of Obstetrics & Gynecology And Reproductive Biologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOsteoporosisen_US
dc.subjectStrontium Ranelateen_US
dc.subjectRaloxifeneen_US
dc.subjectProstaglandinsen_US
dc.subjectRaten_US
dc.subjectProstaglandin E-2en_US
dc.subjectMassen_US
dc.subjectOsteoporosisen_US
dc.subjectEstrogenen_US
dc.subjectIncreasesen_US
dc.subjectPreventsen_US
dc.subjectStrengthen_US
dc.subjectMarrowen_US
dc.subjectPge(2)en_US
dc.titleEffects of strontium ranelate, raloxifene and misoprostol on bone mineral density in ovariectomized ratsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu